Eli Lilly and Company (LLY) — closed signal from October 28, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on January 26, 2026.
Predicted vs. what happened
What happened
Reached its target in 13 days.
The thesis — published October 28, 2025
LLY is a strong, steady grower with positive investor interest and solid results, even if a common chart signal looks soft. Recent positives include a simpler Omvoh plan, a new dividend, and an Olympic partnership that boosts name recognition. Its leading weight-loss and diabetes medicines should keep demand firm over the next 3 months. Main risks are a high share price, tough rivals, and supply limits.
Primary drivers
- Top spot in weight-loss and diabetes drugs should keep demand strong
- FDA okayed an easier Omvoh dosing plan, making care simpler for patients
- Dividend and Olympic tie-up add income and widen public awareness
- High-quality company in a market that currently favors steady growers
How it played out
LLY: target reached in 13 days
Lyra published LLY on 2025-10-28 at 820.07, with 18% expected growth and a 966.26 target. The thesis pointed to demand for weight-loss and diabetes medicines, an easier Omvoh dosing plan, a dividend, an Olympic partnership, and a market that favored steady growers. It also named high share price, tough rivals, and supply limits as risks.
Inside the window, LLY reached the target in 13 days. The peak was 1133.95 on 2026-01-08, a 38.3% gain. It ended the window at 1062.75, still above the target. The thesis played out.
What happened during the window
On 2025-10-30, Axios reported that Lilly raised its 2025 revenue guidance after sales of Mounjaro and Zepbound rose. On 2026-01-07, The Wall Street Journal reported that Lilly was in advanced talks to buy Ventyx Biosciences for around $1 billion.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.